Sensitivity analysis 1 (SA1): Remove people who were prescribed antiplatelet 4 months before cohort entry.
Sensitivity analysis 2 (SA2): In the first objective, limit the study cohort to people who aged 55 or above to explore the impact of potential confounders in young age, for example, pregnancy.
Sensitivity analysis 3: In the second objective, exclude people who were prescribed both warfarin and DOACs on the same day as the latest OAC prescription.
Sensitivity analysis 4 (SA4): In the second objective, exclude people who ever had warfarin prescription 4 months before cohort entry in the DOAC group as warfarin is hypothesised to have harmful effect on severe COVID-19 compared with DOAC. T
Sensitivity analysis 5 (SA5): time-updated exposure variable (warfarin/DOACs) during the follow-up to evaluate the impact of drug switching
Also, update the project.yaml to run the sensitivity analyses
Add sensitivity analysis do-files:
Sensitivity analysis 1 (SA1): Remove people who were prescribed antiplatelet 4 months before cohort entry. Sensitivity analysis 2 (SA2): In the first objective, limit the study cohort to people who aged 55 or above to explore the impact of potential confounders in young age, for example, pregnancy. Sensitivity analysis 3: In the second objective, exclude people who were prescribed both warfarin and DOACs on the same day as the latest OAC prescription. Sensitivity analysis 4 (SA4): In the second objective, exclude people who ever had warfarin prescription 4 months before cohort entry in the DOAC group as warfarin is hypothesised to have harmful effect on severe COVID-19 compared with DOAC. T Sensitivity analysis 5 (SA5): time-updated exposure variable (warfarin/DOACs) during the follow-up to evaluate the impact of drug switching
Also, update the project.yaml to run the sensitivity analyses